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Homocysteine-lowering therapy combined with the standard therapy of patients 
with CHD with В12 deficiency is clinically more effective and more cost effective 
compared to the standard therapy.
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Objectives: As Other EU countries Spain is a decentralized health care system, 
and some measurements were implemented to ensure equity in the system. The 
Therapeutic Positioning Report is a new procedure set up by the Spanish Agency of 
Medicines (AEMPS) and the Ministry of Health in May 2013 as part of the National 
pricing and reimbursement process for new drugs; Its aim was to reduce market 
access timelines and ensure a nation-wide implementation of reimbursement cri-
teria, regional governments participated in this initiative. Our aim was to evaluate 
the implementation of this procedure inside the NOAC drug class. MethOds: We 
developed a structured search by collecting the official reports from the TPR at the 
AEMPS, and the different applications of the NOACs used in Non-Valvular Atrial 
Fibrillation (NVAF) among the 17 Regional Health Systems. These applications were 
evaluated through the different visa inspection procedures that regional govern-
ments use to approve NOAC prescriptions. We summarized this information and fed 
a data collection sheet developed ad hoc to show the differences between regions 
and compared with the National TPR. We evaluated 8 different criteria included in 
the National TPR for NOAC. Results: We found regional differences among the 8 
criteria identified in the NOAC TPR. Main differences were found in key aspects from 
patient access perspective i.e.: different clinical criteria for NOAC indication, allow-
ance of prescription by GPs, INR control criteria to switch from traditional antico-
agulants to NOAC, etc. Three different groups of regions were identified attending to 
the number of criteria coinciding with the TPR. cOnclusiOns: There are different 
patterns of implementation of the TPR at regional level in Spain, leading to different 
access barriers that translate into patient inequities of access and differences in 
NOAC prescription by region.
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Objectives: This study aimed to investigate the relationship between post-PCI 
guideline adherence and 5- year clinical outcomes of post-PCI patients in Hong 
Kong. MethOds: Retrospective data and information was retrieved from the PCI 
registry and electronic patient record system in Prince of Wales Hospital, Hospital 
Authority. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention 
was chosen as reference for post-PCI recommended therapies. Total five post-PCI 
guideline-recommended therapies were included in analysis for the relationship 
with 5-year clinical outcomes, the major adverse cardiac events (MACE). Results: 
Total 276 (68.3%) PCI patients completed 5-year follow-up. Forty-four (15.9%) patients 
experienced MACE in the 5-year period with 23 (52.3%) as cardiac death, 11 (25%) 
as non-fatal myocardial infraction, and 10 (22.7%) as target vascular revasculari-
zation. Only 40 (14.5%) patients fully adhered to all five guideline-recommended 
therapies with a mean total percentage adherence of 77.8%. Diabetes management 
(95.2%) was the most adherent therapy and lipid management was the least adher-
ent therapy (40.7%). Only 64.73% of patients adhered to dual antiplatelet therapy 
with 89.9% and 71.0% of patients adhered to aspirin and clopidogrel respectively. 
Five-year total percentage adherence and dual antiplatelet therapy adherence did 
not significantly correlate with the 5-year clinical outcomes in post-PCI patients. 
However, one of the guideline-recommended therapies, the adherence to aspirin 
was significantly associated with reduced 5-year rates of MACE (adjusted OR 0.071, 
95% CI 0.005-0.981, p = 0.048) and cardiac deaths (adjusted OR 0.036, 95% CI 0.002-
0.742, p = 0.031). The adherence of dual antiplatelet therapy and lipid management 
were significant associated with reduced non-cardiac deaths (adjusted OR 0.224, 
95% CI 0.072-0.700, p = 0.031) and numbers of hospital admissions (adjusted beta 
-0.135, 95% CI -1.126 to -0.035, p = 0.037) respectively. cOnclusiOns: Adherence 
to aspirin, dual antiplatelet therapy, and lipid management were associated with 
better 5-year clinical outcomes in post-PCI patients.
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Objectives: Demonstrate the need for re-opening the debate around the differ-
ent treatment guidelines for Pulmonary Arterial Hypertension (PAH) by asking the 
question: How much money could the UK NHS potentially save if they had a clear a 
ranking of the different oral PAH treatments, based on their clinical effectiveness / 
ICER ratio? Currently the clinical effect ranking of the standard treatments does not 
exist; there only exists a ranking of costs related to each health technology. Once the 
clinical effect ranking is established, the intention of this paper is to investigate how 
this ranking matches/correlates with the ranking of costs and then assess it’s likeky 
impact on the NHS spending, with the intention of making it more efficient - start-
ing from the hypothesis that the current treatment guidelines will be followed for 
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Objectives: the objective of the project is to evaluate the impact of health care 
resources and the related health care costs in relation to outcomes occurred in 10 
years on the cohort of 2002 and intervention on secondary prevention cohort 2010 
with a follow-up to 3 years. MethOds: from 2000 and 2012, Local HealthCare Unit 
(ASLn°1) of Milan identified a cohort of 26.062 patients with RCV (Cardiovascular 
risk). Data analysis was done trough a retrospective claims data study from ASLn°1 
of Milan; Physicians who participated were 494. Information has been collected 
for inclusion in the study regarding some risk factors and treatment. At the end of 
2012 reduced the effects of smoking and BMI after ad hoc training events for physi-
cians. Results: 12,000 subjects were recruited and followed for 3 years with reduc-
tion of spending on the NHS system and reduced incidence of events. A resources 
utilization analysis has been developed using profiles of treatments and dividing 
the population into groups with homogeneous treatment (smoking and BMI control 
vs. standard care), verifying the occurrence of greater outcomes and related health 
care costs. Data are analyzed with the definition of major cardiovascular events, 
all-cause mortality and cause-specific, occurrence of diabetes and other chronic 
greater diseases, verifying the occurrence of greater outcomes and related health 
care costs. 60% of population were > 65 years, 63% were males. Average for paper of 
the risk is 3 for patients over 65 years. The average score is different between males 
and females (4 males and 2 females). cOnclusiOns: administrative databases 
offer low-cost information (since they are already available) regarding more or less 
all services provided in a healthcare environment. These sources and their integra-
tion are a powerful tool supporting conventional methods used in epidemiological 
studies and as tools for plan Healthcare policy.
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Objectives: Heart failure (HF) is a major reason for hospital admissions (HA), with 
a high socio-economic impact. Therefore it is of utmost importance to understand 
how HA due to HF are evolving. This study aimed to build a predictive model for 
the annual number of HA due to HF in Portugal. MethOds: Hospital admissions 
due to HF, between 2003 and 2012, were extracted from National Diagnosis-related 
group database. Demographic and socioeconomic data were collected per district, 
from Statistics Portugal. Generalized linear mixed-effects models (GLMM) were 
used to estimate the annual number of HA. Spatial heterogeneity was corrected 
by considering region-related independent variables (IV): proportion of population 
aged ≥ 65, average monthly income and hospital access. Random effects were con-
sidered for all IV. Results: The fixed effect estimates indicate that, in average, the 
number of HA due to HF increase by 12.4% per year. An increase of 1% in the pro-
portion of population aged ≥ 65 accounts for an increase of 3% in HA. The increase 
of 100€ in the monthly income represents an average decrease of 22.5% in HA. By 
its turn, 1 more hospital per 100,000 inhabitants accounts for an increase of 5.3% 
in HA. These changes are conditional to all the other IV remaining unchanged. 
Estimated random effects accounted for spatial heterogeneity by introducing cor-
rections around the fixed effects. The fitted model was compared to a GLMM without 
random effects for the region-related IV and a fixed effects model. Mean absolute 
deviations (MAD), used to assess goodness of fit, were 34.8, 56.4 and 131, respectively. 
Graphical representation also demonstrated that our model fitted better. Predictive 
ability of the model was assessed by MAD of forecast for 2012 based on 2003-2011 
data (MAD= 77.2). cOnclusiOns: Although this approach produced good results, 
the predictive ability could be further improved by the inclusion of other region-
related variables.
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Objectives: Reasonability of vitamins В6, В12and folic acid (FA) for the preven-
tion of cardiovascular complications in patients with coronary heart disease (CHD) 
is debated. The aim of the study is to assess the cost effectiveness of homocyst-
eine-lowering and standard therapy versus standard therapy in patients with 
CHD. MethOds: Results of the clinical randomized trial [O. O. Shakhmatova, A. 
Komarov, A. N. Samko et al. / Rational Pharmacotherapy in Cardiology, 2011; 7(2), 524-
35]. Cost-effectiveness analysis of homocysteine-lowering therapy by vitamins В6, 
В12and FA combined with the standard therapy versus the standard therapy (anti-
platelet, statin, antihypertensive drugs: ACE inhibitors, beta-blockers) in patients 
with CHD and postPCI, with the elevated level of homocysteine affected by cyano-
cobalamin deficiency. The first level of costs, i.e. the cost of treatment, was taken 
into account. Results: Two treatment regimens were analyzed: the first regimen 
“vitamins + standard”: patients (n= 97) of which since the randomization received 
FA (0.6 mg/day), vitamin В6 (4 mg/day) and vitamin В12 (10 µg/day) along with the 
standard treatment. Patients in the control group (n= 167) received only standard 
therapy. The observation period was 20 months. The first regimen “vitamins + stand-
ard” contributed to reduction of the total combined outcome: cardiovascular death, 
acute coronary syndrome, stroke, revascularization by 95.0%, standard therapy – by 
65.7%. The costs amounted to € 371 for the regimen “vitamins + standard” and € 271 
for the standard therapy, respectively. The “cost-effectiveness” ratio have showed 
that the treatment regimen “vitamins + standard” is more cost effective, its use 
compared to the standard therapy requires additional expenses in the amount of 
€ 307.17 for 1 additional prevented event that did not occurred. cOnclusiOns: 
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hospitalisation, and the modified Rankin Scale (mRS), the most frequently used 
outcome measure in stroke trials. MethOds: Data from all ischemic stroke hos-
pitalizations from a teaching hospital in Belgium were collected between 2006 and 
2009. Data collection included the SOI, patient characteristics (age, gender), risk 
factors (hypertension, smoking, hypercholersterolemia, diabetes, CAD, PAD, previ-
ous stroke), clinical parameters (aorta-atherosclerosis, cancer, TOAST (large-artery 
atherosclerosis, cardioembolism, small-vessel occlusion, other), microbleeds, atrial 
fibrillation, akinesiahypokinesa, endocarditis, MI), functional scales (NiH, mRS), 
repeat events. An ordered multinomial regression estimated the relationship 
between the SOI and these covariates. Using the regression parameters and the 
mean value of the other covariates, predicted values were generated for each com-
bination of the mRS and the SOI. Monte Carlo simulations generated a set of pre-
dicted SOI values per patient (response mapping). Data from 2010 and 2011 were 
used for validation of the regression model. Results: 559 hospitalizations were 
used for the regression analysis. Factors that were discriminating in predicting the 
correct SOI category were the mRS (p< 0.001), age (p= 0.0017), NIH at arrival in hos-
pital (p< 0.001), TOAST (p= 0.0129), atrial fibrillation (0.0217) and repeat in-hospital 
event (p= 0.0031). Generating Monte Carlo predicted values demonstrated good 
concordance across SOI levels at the population level (2.3% vs 2.0% categorized 
in SOI1, 49.8% vs 50.3% in SOI2, 32.9% vs 31.4% in SOI3, 15.4% vs 16.0% in SOI4, for 
the true and the simulated proportions respectively), and the root mean-squared 
error was 0.33. Validation of the data with 588 hospitalizations from 2010 and 2011 
confirmed the good fit of the model. cOnclusiOns: Factors affecting the reim-
bursement/payment level of a stroke admission are age, location of the ischemia, 
atrial fibrillation, scores on stroke functional scales and new in-hospital events.
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Objectives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. Thus, this study was designed to identify epidemiological 
data, screening and treatment guidelines, costs as well as outcome of intravenous 
iron treatment in patients with CHF and iron deficiency. MethOds: A comprehen-
sive literature review was undertaken for all publications from 1998 to September 
2014 using Medline, EMBASE, Cochrane, Science Direct and Pubmed databases, 
comprising English and German articles. The review focused on studies based on 
patients with chronic heart failure and iron deficiency, with or without anemia. 
Articles were systematically selected if they included data for iron deficiency on 
at least one of the following criteria: epidemiology, screening and treatment guide-
lines, costs, clinical outcomes. Results: Database search yielded 5,132 articles 
and 55 additional articles were identified via secondary hand searches. Of the 73 
eligible articles; 30 provided information on epidemiological data, 14 on screening 
and treatment guidelines, 15 on costs and 14 on clinical outcomes. The prevalence 
of CHF ranges between 0.88-6.4%. Out of these, 8-53% suffer from iron deficiency 
depending on the disease severity (New York Heart Association classes - NYHA) 
of heart failure. According to the ESC Guidelines 2012 intravenous iron may be 
considered to improve symptoms, quality of life and exercise capacity based on 
the data of FCM (FAIR-HF, CONFIRM-HF–based on 456 patients). Considering the 
included studies of this review, healthcare expenditure on CHF consumes 1-2% of 
the total healthcare budget. CHF patients with ID induce higher healthcare costs 
compared to non-iron deficient patients (+24%). cOnclusiOns: CHF represents 
a major and growing public health problem and is often associated with ID as 
co-morbidity. IV iron can be an option to improve outcome (patient status), and 
reduce health care costs.
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Objectives: One of the main modifiable risk factors is the blood lipid levels, due 
to changes in lifestyle and treatment. The aim of this study is to characterize total 
cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein 
cholesterol (HDL-C) levels in adults with hypertension, diabetes, HT and DM, and 
CKD, reported to Cuenta de Alto Costo, 2014. MethOds: Descriptive and retrospec-
tive study. The information was obtained from the medical records of approx. 53 
health insurance companies in Colombia. Data from 2.995.061 patients was used. 
Stata 13 was used for data analysis. Qualitative variables were described by its 
frequency distribution. Results: 73% of patients had diagnosis of HT, 6,7% of DM, 
19,6% of HT and DM, and 30% had CKD. In the population with HT, 30,6% had TC 
levels in upper limits and 16,4% in a high level. In patients with DM, 54,3% had 
desirable levels. In patients with both diseases, 25,5% had TC levels in upper limits 
and 14,1% in a high level. In CKD patients, 15% had high level of TC. Regarding HDL 
levels, 56,2% HT patients had HDL levels between 40-60mg/dl. Near 36,1% of DM 
patients had low HDL levels (< 40mg/dl), patients with both diseases had similar 
levels (33,5%). Optimum LDL levels were identified in 42,8% of patients with both 
diseases (HT and DM), in contrast with 32,8% and 35% HTA and DM patients respec-
tively. Around 9% of both diseases had high LDL levels and 4% had very high LDL 
levels. 54% of CKD patients had HDL levels between 40-60mg/dl and 27,8% had 
HDL levels under 40mg/dl. In CKD patients we found that 8,3% had high LDL-C 
levels. cOnclusiOns: patients with both diseases (HT and DM) had better LDL and 
TC levels than patients with other diseases, however HDL-C levels under 40mg/dl 
were higher in this patients group.
this disease. MethOds: Network Meta Analysis using Winbugs (Bayesian, Markov 
chain model using dedicated software), which allows to make an informed decision 
on the clinical effectveness ranking of some of the healthcare technologies (active 
substances) used in the treatment of Pulmonary Arterial Hypertension (PAH). The 
ranking is then compared with the ICER, currently in use by UK NICE and the treat-
ment guidelines set by the UK NHS. Results: Usug the above methods, the ranking 
of healthcare technologies (active substances) used in PAH has been establihed 
and different scenarios have been identified, with regard to increasing efficiency 
of public healthcare expenditure on PAH. cOnclusiOns: The various scenarios 
proposed in this analysis, once confirmed, will contribute to a gain in efficency of 
public healthcare expenditure on PAH in the UK.
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Objectives: Cardiovascular diseases are the leading cause of death and disability 
in the population of most countries, including Ukraine. Ukraine faces a significant 
contribution of cardiovascular diseases in the formation of disability-adjusted life 
year (DALY): men – for 27%, women – for 33% (2013). MethOds: At the end of 
2014 the multidisciplinary working groups on the development of guidelines and 
protocols on different areas of cardiovascular diseases were approved. According 
to the results of a systematic literature review conducted in the databases Medline, 
PubMed, DynaMed, G-I-N etc. ESC, ACCF/AHA and NICE guidelines were selected 
for adaptation in Ukraine. Results: During the meetings the working groups dis-
cussed the opportunities to meet the guidelines’ recommendations in real condi-
tions in Ukraine. For example, there were debates concerning mandatory evaluation 
of highly sensitive troponin on the 99th percentile among patients with NSTEMI, 
or the appointment of new antiplatelet drugs with high evidence base, which were 
not registered in Ukraine at this stage (eg. Prasugrel or Argatroban). The adapted 
guidelines for the treatment of acute and chronic coronary artery disease included 
separate sections with recommendations for revascularization from 2014 ACCF/AHA 
guideline, which allows the doctor to stratify patient against the risk of complica-
tions and identify high-risk patients who should be enforced urgent percutaneous 
coronary intervention. As a result of the work there will be prepared adapted clinical 
guidelines and unified clinical protocols on Acute Coronary Syndromes Without 
ST Segment Elevation, Stable Coronary Artery Disease, Pulmonary Hypertension, 
Prevention of Cardiovascular Disease, Dyslipidemia, Heart Failure, and Atrial 
Fibrillation. cOnclusiOns: Development of medical and technological documents 
on standardization of medical care in cardiovascular diseases will allow to harmo-
nize Ukrainian practice with international recommendations and timely provide 
quality medical care for the relevant areas.
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Objectives: To describe and analyze heart failure (HF) patients, disease path-
way and related healthcare resource use and expenditures in France. MethOds: 
Analysis was based on EGB (“Echantillon Généraliste des Bénéficiaires”) database, 
a permanent random sample (1/97) of the French national healthcare insurance 
system database (SNIIRAM), linked with the national hospital discharge summary 
database (PMSI). Patients were selected on the following criteria: HF classified 
as long-term disease (ALD scheme) in 2012 and/or at least 1 HF hospitalization 
(ICD-10 codes) on 2008-2012 period and/or at least 3 reimbursements of HF rec-
ommended drugs (including beta-blockers (BB), angiotensin-converting-enzyme 
inhibitors (ACEi), angiotensin-receptor-blockers (ARB), diuretics, digoxin, ivabradine) 
in 2012. Results: 12,981 patients (average age: 74.8 years; 51.6% of men) were 
included, representing a HF prevalence of 2.2% in the total French population. Most 
of patients visited a general practitioner (93.1%) on regular basis (9.3 visits/year), but 
only few of them visited a cardiologist (37.0%) through the year (0.67 visit/year). HF 
recommended drugs were not prescribed to all patients (BB: 60.3%; ACEi/ARB: 53,3%; 
diuretics: 46.0%) and the recommended triple therapy (BB+ACEi/ARB+diuretics) was 
prescribed to only few of them (16.4%). Almost half of patients (47.3%) were hospital-
ized within the year (1.3 hospitalizations/year), with a quarter of these hospital stays 
related to HF (27.0%). The annual age-standardized mortality rate was 4.6 higher 
than in the full EGB database (939.0 versus 71.1 per 10,000 persons). Annual aver-
age healthcare costs were 7,956€ /patient, mostly driven by hospitalizations (3,683€ ; 
46,3%), drugs (1,287€ ; 16,2%), paramedical visits (980€ ; 12,3%) and medical visits 
(464€ ; 5,8%). cOnclusiOns: Patients are not optimally managed for their HF, with 
a limited healthcare resource use. Despite a high rate of hospitalization, cardiologist 
visits remain at a very low frequency in this HF population. Better referring these 
patients to cardiologists should improve their management and optimize drugs 
prescription as recommanded in the guidelines.
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Objectives: To investigate the relationship between the APR-DRG severity of ill-
ness index (SOI) used to determine the reimbursement/payment level for stroke 
